Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Cost Comparison: Oral vs Injectable

Cost varies by formulation, source, and dosing protocol. These estimates reflect typical 2026 market pricing for research-grade products. Peptide cost (30-day supply) $60-100 Bacteriostatic water Not needed $8-15 Syringes (30-day supply) $10-20 Alcohol swabs $

This comparison does not assign a generated winner or score.

  • Cost varies by formulation, source, and dosing protocol. These estimates reflect typical 2026 market pricing for research-grade products.
  • Peptide cost (30-day supply)
  • $60-100
  • Bacteriostatic water
  • Not needed
  • $8-15
  • Syringes (30-day supply)
  • $10-20
  • Alcohol swabs
  • $5-8
  • Total monthly cost
  • $83-143
  • Cost per mcg delivered systemically (acetate)
  • High (~$0.08/mcg reaching blood)
  • Low (~$0.002/mcg reaching blood)
  • Cost per mcg delivered systemically (arginate)
  • Lower (~$0.003/mcg reaching blood)
  • The raw capsule price is lower, but cost-per-effective-mcg tells a different story for acetate capsules. With 3% bioavailability, you need roughly 8,300 mcg orally to deliver the same 250 mcg systemically that a single injection provides. Arginate capsules close this gap dramatically.
  • For GI healing, cost-per-effective-mcg is misleading because systemic absorption is not the goal. The local effect on gut tissue occurs at full oral dose regardless of bioavailability. If your target is the GI tract, oral capsules are both cheaper and more effective.
  • For supplies needed with injectable protocols, see our peptide reconstitution calculator and guide on how to reconstitute peptides.
More references

Related material

Comparison

Side Effect Comparison by Route

Each route produces a distinct side effect profile. The differences trace directly to pharmacokinetics. Nausea Common (20-30%) Rare (<5%) Direct GI mucosal contact Diarrhea Common…

View details →
Comparison

BPC-157 Oral vs Injectable

BPC-157 Oral vs Injectable A 2026 UK research review of BPC-157 oral versus injectable administration — the preclinical evidence for retained oral activity, gastric-survival mecha…

View details →